Background
Phase 2, single-arm; Australasian Leukaemia and Lymphoma Group (ALLG). Newly diagnosed, genetically confirmed PML-RARA acute promyelocytic leukaemia (APL), including high-risk patients. Tested moving arsenic trioxide (ATO) into front-line induction and consolidation to lower relapse. N=124.
Results
Interventions and follow up: Treatment: induction with ATRA 45 mg/m²/day (days 1-36) + age-adjusted IV idarubicin 6-12 mg/m² (days 2,4,6,8) + IV ATO 0.15 mg/kg/day (days 9-36), plus prednisone prophylaxis for differentiation syndrome; 2 consolidation cycles of ATRA + ATO (chemo-free); then 2 yr maintenance ATRA + oral methotrexate + 6-mercaptopurine (n=124).
Primary endpoint: co-primary freedom from relapse and early death (≤36 days), vs historical APML3 (no ATO).
mFollow up: 4.2 yr (IQR 3.2–5.2).
Results: Remission: 118/124 (95%) hematologic CR; all 112 starting consolidation reached molecular CR.
5yr FFR: 95% (95% CI 89–98); vs APML3 HR 0.23, 95% CI 0.08–0.64, P=.002.
5yr DFS: 95% (89–98); HR 0.21, 95% CI 0.07–0.59, P=.001.
5yr EFS: 90% (83–94); HR 0.34, 95% CI 0.16–0.69, P=.002.
5yr OS: 94% (89–97); HR 0.35, 95% CI 0.14–0.91, P=.02.
Primary endpoint: co-primary freedom from relapse and early death (≤36 days), vs historical APML3 (no ATO).
mFollow up: 4.2 yr (IQR 3.2–5.2).
Results: Remission: 118/124 (95%) hematologic CR; all 112 starting consolidation reached molecular CR.
5yr FFR: 95% (95% CI 89–98); vs APML3 HR 0.23, 95% CI 0.08–0.64, P=.002.
5yr DFS: 95% (89–98); HR 0.21, 95% CI 0.07–0.59, P=.001.
5yr EFS: 90% (83–94); HR 0.34, 95% CI 0.16–0.69, P=.002.
5yr OS: 94% (89–97); HR 0.35, 95% CI 0.14–0.91, P=.02.
Adverse events
Early deaths: 4 (3%) within 36 days.
Deaths in remission: none.
Design features: schedule limited cardiotoxicity and differentiation-syndrome severity (prednisone prophylaxis); reduced cumulative anthracycline exposure was deliberate.
Deaths in remission: none.
Design features: schedule limited cardiotoxicity and differentiation-syndrome severity (prednisone prophylaxis); reduced cumulative anthracycline exposure was deliberate.
Conclusions
Adding ATO to ATRA + idarubicin in both induction and consolidation produced excellent long-term outcomes with markedly reduced relapse risk vs historical controls, while substantially lowering anthracycline exposure. Helped establish ATO as a front-line component of APL therapy.
Key Limitations
Non-randomised single-arm trial; comparisons relied on the historical APML3 control rather than a contemporaneous randomised arm, leaving uncertain how much benefit derived from ATO versus other differences. Idarubicin was retained in induction, so APML4 was not chemotherapy-free and does not directly address whether anthracyclines can be omitted entirely in non-high-risk APL.
Clinical Context
Among the studies cementing ATO's role in initial APL management. For low/intermediate-risk APL, the randomised ATRA-ATO data (Lo-Coco, APL0406) established a chemo-free standard now endorsed by ESMO and ASCO; APML4's anthracycline-containing backbone remains relevant for high-risk disease, where the optimal integration of ATO and chemotherapy continues to be discussed in ESMO guidelines. ATO supports a largely chemo-sparing frontline approach in APL.